THANK YOU FOR SUBSCRIBING
Built with a singular focus on science research, pharmaceutical, and biopharmaceutical manufacturing, Sartorius is well-positioned as a comprehensive solutions provider across the value chain from R&D, production, to in-process Quality Control (QC). “Covering the entire value-added chain of the biopharmaceutical, Sartorius products and services ensure novel therapies reach the market faster and are more accessible to more people worldwide,” mentions Grace Johnston, Head of Marketing at Sartorius.
Sartorius Bioprocess Division provides innovative single-use products and equipment for the manufacture of biologics, enabling more efficient and less expensive production. Through the Bioprocess Solutions Division, Sartorius offers a broad product portfolio that covers all steps in the production of a biopharmaceutical. The company’s core technologies, such as filtration, fermentation, cell cultivation, and single-use bags and containers have been leading market positions for years. Sartorius’ Laboratory Products and Services Division, on the other hand, equips laboratories performing research and quality control with premium lab essentials—market-leading laboratory products, consumables, and services—to simplify workflows and advance speed to market.
Sartorius’ revolutionary technologies including the iQue Screener PLUS provide rapid, multifactorial results to enable deeper insights and ensure the choice, quality, and integrity of the client’s biopharmaceutical product. Sartorius’ revolutionary technologies including the iQue Screener PLUS provide rapid, multifactorial results to enable deeper insights and ensure the choice, quality, and integrity of the client’s biopharmaceutical product.
Covering the entire value-added chain of the biopharmaceutical, Sartorius products and services ensure novel therapies reach the market faster and are more accessible to more people worldwide
“Keeping in mind that safety and compliance are critical in the sampling, detection and microbiological quantification processes, our microbiological QC portfolio—air monitoring, bioburden, and sterility testing—comprises fit-for-purpose, easy-to-use, and efficient tools that are specifically designed to help our customers monitor and reduce contamination risks,” mentions Sook Yee Loh, Head of Sales, Life Science Research, APAC at Sartorius. Collaboratively, both these divisions enable Sartorius’ customers to manufacture traditional drugs and biopharmaceuticals safely, more efficiently, and less expensively.
As a trusted partner for the biopharmaceutical industry and laboratories, Sartorius plays a vital role in regulatory compliance along with providing tools that enable customers to stay at the cutting-edge of innovation. The uniqueness of Sartorius stems from its acquisitions of U.S. companies: IntelliCyt and Essen BioScience in the field of cell analytics. Powered by a combination of unique technologies in the area of high throughput (IntelliCyt) and real-time quantitative analysis (Essen), Sartorius’ unrivaled solutions provide significant benefits to biopharmaceuticals’ R&D workflows.
Sartorius also continues to innovate in the space of lab weighing. Loh and Eirik Pettersen, Head of Sales, Applied Research, LPS Division, inform, “In March 2019, we launched Cubis II®, the next generation of modular premium balances for scientists in R&D and analytical laboratories needing the most reliable lab weighing results. Sartorius’s Cubis® II is the first balance that supports all requirements to achieve 21 CFR part 11 and EU Annex 11 compliance without needing a single sheet of paper and eliminating the possibility to falsify process data and/or signatures.”
With over 8000 employees, Sartorius owns and operates production facilities in Europe, America, and Asia, as well as enjoys a presence in 110 counties. The corporate culture at the firm is shaped by three core values: sustainability, openness, and enjoyment. “These form the bedrock of our company’s innovative and competitive strength,” asserts Johnston. As for the future, Sartorius has aggressive expansion plans to optimally continue serving the growing needs in the market. In 2019, Sartorius is all set to complete the major part of its multi-year investment program to expand the production capacity of its manufacturing facilities and extend its group headquarters. “Furthermore, Sartorius’ strategic initiatives for 2025 in the APAC region will center on building upon our strong China market presence, adding high impact innovations to our product portfolio and extending our manufacturing base in Asia,” concludes Loh.
Employment of Latest Bioreactor Vessel for Gene and Cell Therapy Applications
The new bioreactor vessel is designed for optimum growth and gentle stirring of cell lines, which is a cost-effective and scalable process in developing gene therapies and cell.
FREMONT, CA: “Covering the entire value-added chain of biopharmaceuticals, Sartorius products and services ensure novel therapies reach the market faster and are more accessible to more people worldwide,” mentions Grace Johnston, Vice President Marketing at Sartorius while talking about the focus of the enterprise. Sartorius Stedium Biotech, a chief global partner of the biopharmaceutical industry recently announced the launch of a new vessel for its ambr 250 modular benchtop automated mini bioreactor system.